A Phase III study carried out by Novartis has demonstrated that Afinitor (everolimus) tablets coupled with exemestane can more than double the time women with breast cancer live without tumour growth.

The results of the trial also suggested that the combined therapy also helps to reduce the risk of cancer progression by 57% versus exemestane alone.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study involved 724 postmenopausal women with ER+HER2- advanced breast cancer that recurred or progressed either on or following previous treatment with hormonal therapies letrozole or anastrozole.

The company plans to submit data from the trial for regulatory approvals by the end of 2011.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact